Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Adlai Nortye

Request full access

Adlai Nortye engages in research and development of biopharmaceuticals for cancer immunotherapy

Hangzhou, ChinaFounded 2004Biotech & Life Sciences

About Adlai Nortye

Adlai Nortye is a clinical-stage, global biopharmaceutical company with a dual presence in the United States and China, operating research and development as well as clinical operation centers in both countries. Founded in 2004, the company focuses on developing treatments for cancer through a strategy that combines in-house research with collaborative innovation. The company is led by founder, Chairman, and CEO, Lu Yang.

Adlai Nortye's business model is centered on the discovery, development, and commercialization of oncology therapies. It has established a pipeline of drug candidates targeting various cancers, aiming to address significant unmet needs in the global oncology market. The firm generates value by advancing these candidates through the rigorous phases of clinical trials, with the ultimate goal of obtaining regulatory approval and bringing new treatments to patients worldwide. Strategic partnerships with other leading pharmaceutical companies are a key component of its approach, enabling the co-development of promising therapies.

The company's product pipeline includes several candidates at different stages of clinical development. AN2025 (buparlisib), a PI3K inhibitor, has received Fast Track Designation from the FDA and is in a global Phase III trial. It is being studied in combination with paclitaxel as a potential second-line treatment for patients with recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) who have not responded to PD-1 inhibitors. Another key candidate is AN0025 (palupiprant), an EP4 antagonist designed to modulate the tumor microenvironment. It is currently in a Phase Ib trial in combination with Keytruda® for various solid tumors and a Phase II study with chemoradiotherapy for locally advanced cancers. Furthermore, Adlai Nortye is developing AN4005, an internally developed oral small molecule PD-L1 inhibitor, which is undergoing Phase I trials in both the U.S. and China. The company is also exploring a triple combination therapy using AN2025, AN0025, and Roche's Tecentriq for solid tumors with PI3KCA mutations.

Source: Dealroom company data

At a glance

Status
Operational
Employees
65
Open positions
2
Dealroom signal
45.6/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

8 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
PRIVATE PLACEMENT NON VCOther financing Apr 2026 $150M — Casdin Capital · Perceptive Advisors · Kalehua Capital Management · Cormorant Asset Management ↗
PRIVATE PLACEMENT NON VCOther financing Feb 2026 $140M — Cormorant Asset Management · Balyasny Asset Management · Casdin Capital · Point72 ↗
Showing the latest 2 of 8 recorded eventsBook a demo for the full funding history →

Growth signals

Adlai Nortye website traffic

Latest recorded traffic for Adlai Nortye is 5.8K monthly website visits, up 48.7% over the last three months. Adlai Nortye's team grew 4.8% over the past year.

Latest monthly visits5.8K 3-month web change+48.7% 1-year team growth+4.8%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom
1 distinct opening shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
Amygdala NeuroscienceAmygdala's mission is to address the growing unmet need associated with substance use disorder by discovering, developing and commercializing safe and effective pharmacotherapies to treat and prevent addiction Palo Alto, United States Operational 3 $7.6M —
Beckley PsytechClinical-stage biotechnology developing rapid-acting psychedelic medicines Beckley and Stowood, United Kingdom Operational
Nucleome TherapeuticsDecoding the dark matter of the human genome to discover first-in-class precision medicine Oxford, United Kingdom Operational
Rosa BiotechAI-driven biosensing and diagnostics company providing outcome-focused biosensing for early disease diagnosis and for use in industrial biotechnology Bristol, United Kingdom Operational
EmpiricoHuge biological datasets, human genetics, and programmable biology to power novel target discovery and development San Diego, United States Operational
BraeburnBraeburn is dedicated to delivering solutions for people living with the serious, often fatal consequences of opioid addiction Washington DC, United States Operational
PredxBioTissue-Based Decision Intelligence for Oncology Bellevue, United States Operational
BiofourmisBiotechnology company that augments personalized care and therapies using digital therapeutics Boston, United States Operational
Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Adlai Nortye in the Hangzhou ecosystem

Live from Dealroom

The Adlai Nortye office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

18 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

Series B and later5 investors entered at this stage

  • Legend Star
  • Hangzhou Tigermed
  • CMG-SDIC Capital
  • Tigermed
  • WuXi Biologics

Other known investors10 additional known investors

Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
4 countries with
team presence
🇨🇳 China55.6%
🇺🇸 United States37%
🇨🇦 Canada3.7%
🇭🇰 Hong Kong3.7%
4 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Adlai Nortye on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Adlai Nortye’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.